Navigation Links
Chinese scientists Zhen-Yi Wang and Zhu Chen awarded 7th annual Szent-Gyorgyi Prize
Date:2/6/2012

BETHESDA, Maryland (Feb. 6, 2012) The National Foundation for Cancer Research announced today that Dr. Zhen-Yi Wang and Dr. Zhu Chen have been awarded the 7th annual Szent-Gyrgyi Prize for Progress in Cancer Research for their innovative research that led to the successful development of a new therapeutic approach to acute promyelocytic leukemia (APL).

By combining traditional Chinese medicine with Western medicine, Drs. Wang and Chen have provided dramatic improvement in the five-year disease-free survival rate of APL patients from approximately 25 percent to 95 percent making this therapy a standard of care for APL treatment throughout the world, and turning one of the most fatal diseases into a highly curable one.

"I am so glad to see that the efforts we have devoted to research on leukemia these last several decades have led to solid clinical benefits to APL patients around the world," said Dr. Wang. "This award will inspire us as we continue our efforts to find more effective therapies to treat cancers."

"This is a great honor for Dr. Wang and me; it is quite humbling to know that our respected colleagues from many scientific disciplines have selected us for this prestigious award," said Dr. Chen, who also serves as China's Minister of Health. "Scientists across the globe are working every day to cure cancer. I hope our work may continue to inspire others."

A clinical researcher at the Ruijin Hospital in Shanghai in the early 1980s, Dr. Zhen-Yi Wang performed the first successful therapy on APL patients using all-trans retinoic acid (ATRA), which significantly increased the survival rate of patients with APL. Dr. Zhu Chen, a former student of Wang, made major contributions to the identification of the molecular mechanisms of both ATRA and arsenic trioxide in APL. He also demonstrated in clinical trials that arsenic trioxide, a compound used as a traditional Chinese medicine for over 2,400 years, is effective against APL. Since the 1990s, Drs. Wang and Chen have worked together to conduct clinical trials combining ATRA and arsenic trioxide to treat APL patients, with great success.

"Drs. Wang and Chen have quite literally changed the face of medicine for patients suffering from APL. Their combined work has saved countless lives and will continue to save many more lives around the world both today and in future generations," said Dr. Beatrice Mintz, Fox Chase Cancer Center, Chair of the 7th Selection Committee of Szent-Gyrgyi Prize and winner of the 6th Annual Albert Szent-Gyorgyi Prize. "Terminal differentiation of cancer cells has been an important focus in my research, and I am very happy about the successful clinical application of this principle by Drs. Wang and Chen. I cannot imagine a better testament to the outcomes of investing in cancer research than what these two distinguished scientists have achieved."

"In keeping with the spirit of nonconformity for which NFCR founder Albert Szent-Gyrgyi is known, the selection of Drs. Wang and Chen has a significant meaning for those who work in the trenches of cancer research each day," said Sujuan Ba, Ph.D., co-chair of the Szent-Gyrgyi Prize Selection Committee and chief operating officer of NFCR. "True scientific discovery comes from innovative ideas and dedicated research. These two scientists are inspirational, as they both have devoted their lives to this work that will impact the world for generations to come."


'/>"/>

Contact: Silas Deane
silas.deane@nfcr.org
615-319-6007
Deane, Smith & Partners
Source:Eurekalert

Related biology news :

1. Male crickets with bigger heads are better fighters, study reveals, echoing ancient Chinese text
2. Chinese slimming capsules
3. Reintroduced Chinese alligators now multiplying in the wild in China
4. Scientists help explain effects of ancient Chinese herbal formulas on heart health
5. Chinese medicine societies reject tiger bones ahead of CITES conference
6. U-M joins with Chinese university to jointly fund renewable energy and biomedical research projects
7. Study uses Chinese wolfberries to improve vision imperfections caused by type-2 diabetes
8. Chinese scientists discover marker indicating the developmental potential of stem cells
9. Revealing the ancient Chinese secret of sticky rice mortar
10. Chinese-German collaboration yields new species of Large Blue butterfly
11. Most panda habitat is outside nature reserves according to joint MSU-Chinese research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
(Date:2/7/2017)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the latest release ... flexible and award winning eClinical solution, is now available ... is a proven Software-as-a-Service (SaaS) clinical research technology platform ... also delivers an entire suite of eClinical tools to ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... The Fight Against Cancer Innovation Trust (FACIT) and the ... report that Fusion Pharmaceuticals Inc. (Fusion) has closed a ... – JJDC, Inc. (JJDC) as the lead investor. Additional, ... and Genesys Capital, as well as founding investor FACIT.  ... ...
(Date:2/23/2017)... it seems everyone has a chance to express their personalities. ... and dynamic community unlike any other. The businesses that succeed ... With their newest salon in Dunwoody ... that tradition with a unique, fresh approach to head lice ... newest of 13 nationwide locations, each of them well-situated in ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
(Date:2/23/2017)... Baltimore, Maryland (PRWEB) , ... ... ... firm, PathSensors, Inc., announced today that in a published evaluation of multiple ... (PNNL), a U.S. Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection ...
Breaking Biology Technology: